How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC).   We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included: The role of surgery and adjuvant chemotherapy in early-stage SCLC. Insights into the ADRIATIC study, which highlighted the efficacy of Durvalumab in limited-stage disease. The debate surrounding prophylactic cranial irradiation (PCI) and its implications for patient care. The latest findings from the IMforte study, showcasing the combination of Atezolizumab and Lurbinectedin as a new standard of care in extensive-stage SCLC. The promising results of Tarlatamab in the second-line setting and its impact on overall survival.   Join us as we explored these advancements and their potential to improve patient outcomes in the fight against small cell lung cancer.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers